{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:50:27Z","timestamp":1768823427994,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01 CE0022778"],"award-info":[{"award-number":["U01 CE0022778"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jsat.2021.108634","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:32:05Z","timestamp":1632778325000},"page":"108634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Spatial proximity and access to buprenorphine or methadone treatment for opioid use disorder in a sample of people misusing opioids in Southern California"],"prefix":"10.1016","volume":"132","author":[{"given":"P.J.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Faul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.L.","family":"Gaines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jsat.2021.108634_bb0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11414-018-9586-y","article-title":"Disparities in the treatment of substance use disorders: does where you live matter?","volume":"45","author":"Acevedo","year":"2018","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.jsat.2021.108634_bb0010","series-title":"SAMHSA National Survey of Substance Abuse Treatment Services: The CBHSQ Report","article-title":"Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update)","author":"Alderks","year":"2017"},{"issue":"2","key":"10.1016\/j.jsat.2021.108634_bb0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: A US Nationwide small area analysis","volume":"24","author":"Amiri","year":"2021","journal-title":"Value in Health"},{"issue":"1","key":"10.1016\/j.jsat.2021.108634_bb0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.jsat.2021.108634_bb0030","series-title":"California HIV surveillance report\u20142017","first-page":"16","year":"2017"},{"issue":"17","key":"10.1016\/j.jsat.2021.108634_bb0040","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamainternmed.2013.9059","article-title":"Responses of state medicaid programs to buprenorphine diversion: Doing more harm than good?","volume":"173","author":"Clark","year":"2013","journal-title":"JAMA Internal Medicine"},{"issue":"8","key":"10.1016\/j.jsat.2021.108634_bb0045","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1377\/hlthaff.2010.0532","article-title":"The evidence doesn\u2019t justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine","volume":"30","author":"Clark","year":"2011","journal-title":"Health Affairs"},{"key":"10.1016\/j.jsat.2021.108634_bb0050","series-title":"California county fact sheets: Treatment gaps in opioid-agonist medication assisted therapy (OA-MAT) and estimates of how many additional prescribers are needed","first-page":"67","author":"Clemens-Cope","year":"2019"},{"issue":"5","key":"10.1016\/j.jsat.2021.108634_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9708","article-title":"Extended-release buprenorphine and its evaluation with patient-reported outcomes","volume":"4","author":"Compton","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2021.108634_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108093","article-title":"Geographic access to buprenorphine prescribers for patients who use public transit","volume":"117","author":"Drake","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1016\/j.jsat.2021.108634_bb0065","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108634_bb0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/epirev\/mxh007","article-title":"The social epidemiology of substance use","volume":"26","author":"Galea","year":"2004","journal-title":"Epidemiologic Reviews"},{"key":"10.1016\/j.jsat.2021.108634_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.029","article-title":"U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder","volume":"204","author":"Ghertner","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108634_bb0080","doi-asserted-by":"crossref","first-page":"e203711","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.jsat.2021.108634_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.drugalcdep.2007.11.021","article-title":"A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification","volume":"94","author":"Gruber","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.jsat.2021.108634_bb0095","doi-asserted-by":"crossref","first-page":"e196373","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.jsat.2021.108634_bb0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"The Annals of Family Medicine"},{"issue":"6408","key":"10.1016\/j.jsat.2021.108634_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jsat.2021.108634_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties","volume":"93","author":"Jones","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2021.108634_bb0115","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/10550490802266276","article-title":"Methadone maintenance vs. methadone taper during pregnancy: Maternal and neonatal outcomes","volume":"17","author":"Jones","year":"2008","journal-title":"The American Journal on Addictions"},{"issue":"3","key":"10.1016\/j.jsat.2021.108634_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/00952990.2011.643983","article-title":"A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients","volume":"38","author":"Kelly","year":"2012","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2021.108634_bb0125","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.drugalcdep.2016.08.642","article-title":"Buprenorphine physician supply: Relationship with state-level prescription opioid mortality","volume":"173","author":"Knudsen","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108634_bb0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0b013e3181cc9610","article-title":"Patients\u2019 reasons for choosing office-based buprenorphine: Preference for patient-centered care","volume":"4","author":"Korthuis","year":"2010","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2021.108634_bb0135","doi-asserted-by":"crossref","DOI":"10.2202\/1941-2851.1007","article-title":"United States government oversight and regulation of medication assisted treatment for the treatment of opioid dependence","volume":"2","author":"Kresina","year":"2009","journal-title":"Journal of Drug Policy Analysis"},{"issue":"1","key":"10.1016\/j.jsat.2021.108634_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10826084.2015.1089905","article-title":"Buprenorphine maintenance treatment of opiate dependence: Correlations between prescriber beliefs and practices","volume":"51","author":"MacDonald","year":"2016","journal-title":"Substance Use & Misuse"},{"issue":"6","key":"10.1016\/j.jsat.2021.108634_bb0145","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1360-0443.2004.00728.x","article-title":"Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification","volume":"99","author":"Masson","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108634_bb0150","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2021.108634_bb0155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0376-8716(97)01348-3","article-title":"Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts","volume":"45","author":"Miotto","year":"1997","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108634_bb0160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2021.108634_bb0170","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment","volume":"36","author":"Netherland","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2021.108634_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1747-597X-4-3","article-title":"Differences in service utilization and barriers among blacks, hispanics, and whites with drug use disorders","volume":"4","author":"Perron","year":"2009","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"2","key":"10.1016\/j.jsat.2021.108634_bb0180","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1440-1614.2002.01012.x","article-title":"Naltrexone in the treatment of heroin dependence: Relationship with depression and risk of overdose","volume":"36","author":"Ritter","year":"2002","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108634_bb0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"The Annals of Family Medicine"},{"issue":"5","key":"10.1016\/j.jsat.2021.108634_bb0190","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550490802268835","article-title":"Attitudes toward buprenorphine and methadone among opioid-dependent individuals","volume":"17","author":"Schwartz","year":"2008","journal-title":"The American Journal on Addictions"},{"issue":"10","key":"10.1016\/j.jsat.2021.108634_bb0195","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jama.283.10.1303","article-title":"Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial","volume":"283","author":"Sees","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jsat.2021.108634_bb0200","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jurban\/79.4.571","article-title":"Beliefs about methadone in an inner-city methadone clinic","volume":"79","author":"Stancliff","year":"2002","journal-title":"Journal of Urban Health"},{"key":"10.1016\/j.jsat.2021.108634_bb0215","series-title":"Facing addiction in America: The surgeon general\u2019s spotlight on opioids","first-page":"40","year":"2018"},{"issue":"22","key":"10.1016\/j.jsat.2021.108634_bb0220","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014Tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2021.108634_bb0225","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers","volume":"23","author":"Walley","year":"2008","journal-title":"Journal of General Internal Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2021.108634_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229787","article-title":"Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007\u201316","volume":"15","author":"Yang","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jsat.2021.108634_bb0235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/ijerph6020787","article-title":"Attitudes toward methadone among out-of-treatment minority injection drug users: Implications for health disparities","volume":"6","author":"Zaller","year":"2009","journal-title":"International Journal of Environmental Research and Public Health"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:58:14Z","timestamp":1760039894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221003603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"alternative-id":["S0740547221003603"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108634","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatial proximity and access to buprenorphine or methadone treatment for opioid use disorder in a sample of people misusing opioids in Southern California","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108634"}}